Thursday, February 21, 2013

Recent new drug approvals


1. Icosapent ethyl (Vascepa)

  • Indication: Adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500mg/dL) hypertriglyceridemia. 
  • Pharmacology: Icosapent ethyl is an ethyl ester of the omega-3 fatty acid eicosapentaenoic acid (EPA).
  • Studies suggest that eicosapentaenoic acid reduces hepatic very low-density lipoprotein triglycerides (VLDL-TG) synthesis and/or secretion and enhances TG clearance from circulating VLDL particles.
  • Potential mechanisms of action include 
    • increased ß-oxidation;
    •  inhibition of acyl-CoA:1,2-diacylglycerol acyl­transferase (DGAT); 
    • decreased lipogenesis in the liver; and
    •  increased plasma lipoprotein lipase activity.
2. Cabozantinib (Cometriq)

  • Indication

    :

Treatment of progressive, metastatic medullary thyroid cancer.

  • Pharmacology:

    • Cabozantinib inhibits the tyrosine kinase activity of RET, MET, VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, and TIE-2. 
    • These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment.


Free Books, powerpoint presentations, teaching tools and resources and drug information